To: [redacted])[[redacted]@minvws.nl]
From: [redacted])
Sent: Fri 12/18/2020 1:51:24 PM
Subject: RE: SENSITIVE - possible joint procurement of monoclonal antibodies
Received: Fri 12/18/2020 1:51:25 PM

Ha [redacted]

Snap ik. Hopelijk tot straks,

Groet,
[redacted]

Van: [redacted]) <[redacted]@minvws.nl>
Verzonden: vrijdag 18 december 2020 13:15
Aan: [redacted]) <[redacted]@minvws.nl>
Onderwerp: RE: SENSITIVE - possible joint procurement of monoclonal antibodies

Hoi [redacted]
Fijn dat het [redacted] Ik ben nog bezig met flink wat laatste dingen en dan in principe twee weken vrij. Ik probeer je vanmiddag nog even te bellen,
[redacted]

Van: [redacted]) <[redacted]@minvws.nl>
Verzonden: vrijdag 18 december 2020 11:55
Aan: [redacted]) <[redacted]@minvws.nl>
Onderwerp: FW: SENSITIVE - possible joint procurement of monoclonal antibodies

Haj [redacted],

Ik ben vandaag weer begonnen, met name met het wegwerken van mijn mail. [redacted]

Ik zie nu ook onderstaande over de JP. Verder loopt dat verhaal met Astra Zenica natuurlijk nog. Ik zou het wel handig vinden om even bij te praten? Dat kan eventueel vandaag. Ik ben in principe volgende week vrij en werk daarna weer vanaf maandag 28 december. En jij? Mocht jij die tweede week van het kerstreces bereikbaar zijn, kunnen we ook begin die week even bellen om de klokken weer gelijk te zetten?

Groet,
[redacted]

Van: [redacted]) <[redacted]@minvws.nl>
Verzonden: woensdag 16 december 2020 18:03
Aan: [redacted]@ec.europa.eu' <[redacted]
[redacted]@ec.europa.eu>
CC: [redacted]
Onderwerp: RE: SENSITIVE - possible joint procurement of monoclonal antibodies

Dear sir/madam

Further to your queries below please find the responses from the Netherlands:

Please send us the answers to the 3 questions posed in the meeting by tomorrow, Wed 16 Dec cob.
The questions are:

Are you considering national emergency authorization of any antibody from the 4 companies presented or other?

No

Would you be interested in a joint procurement / reservation agreement with any of the companies?

Yes, where we want to underscore the need for a proof of added therapeutic value, transparency on price setting by the manufacturar and public transparency on the negotiated purchase price.

Are you able to estimate your needs for the next months?

No at this time this is not possible as there are substantial uncertainties about the value of the products and which indication / patient populations the products will be targeted to. And there are currently uncertainties on the demand side: number of patients in need as a function of timing of availability of the products and roll out status of vaccinations

With best regards

5.1.2e
Ministry of Health, The Netherlands

Van: 5.1.2e @ec.europa.eu < 5.1.2e
5.1.2e @ec.europa.eu>
Verzonden: dinsdag 15 december 2020 16:18
Aan: 5.1.2e @ec.europa.eu
CC: 5.1.2e 5.1.2e < 5.1.2e @ec.europa.eu>; 5.1.2e < 5.1.2e @ec.europa.eu>
Onderwerp: SENSITIVE - possible joint procurement of monoclonal antibodies

SENSITIVE: Limited Joint Procurement of medical countermeasures*

Dear Members of the Steering Committee for a possible joint procurement of monoclonal antibodies,

Further to our meeting yesterday, please find below information on the monoclonal antibodies currently under investigation:

Bamlanivimab (ELi Lilly): authorized for COVID-19 patients who are 12 years of age and older weighing at least 40 kilograms, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

This includes those who are 65 years of age or older, or who have certain chronic medical conditions.

https://www.fda.gov/media/143602/download

The "cocktail" of casirivimab and imdevimab (Regeneron/Roche (in Europe) to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms and who are at high risk for progressing to severe COVID-19.

This includes those who are 65 years of age or older or who have certain chronic medical conditions.

https://www.fda.gov/media/143891/download

Monoclonal anti-bodies (Otilimab and VIR 7831) from GSK

On Otilimab:
https://clinicaltrials.gov/ct2/show/NCT04376684

On VIR 7831:
https://clinicaltrials.gov/ct2/show/NCT04545060

Regdanvimab - CT-P59 from the South Korean company Celltrion

https://clinicaltrials.gov/ct2/show/NCT04602000

Also: EMA has provided (unpublished advice) on otilimab and CT-P59.

Please send us the answers to the 3 questions posed in the meeting by tomorrow, Wed 16 Dec cob.
The questions are:

- Are you considering national emergency authorization of any antibody from the 4 companies presented or other?
- Would you be interested in a joint procurement / reservation agreement with any of the companies?
- Are you able to estimate your needs for the next months?

Kind regards,

The Joint Procurement Agreement Team

_____